Overview

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Status:
Not yet recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Medical University

Treatments:

Apatinib
Oxaliplatin
Paclitaxel